Sigma Healthcare Limited (SIG.AX) — Equity Research Report

Sigma Healthcare Limited

SIG.AX | Healthcare / Pharmacy Retail | ASX | Method B

A$2.66

Current Price

Report Date: 30 March 2026

FY End: 30 June

Market Cap

A$30.6B

A$31.2B

P/E (FY2025)

57.7×

Fwd P/E FY2026E

40.3×

EV/EBITDA Fwd

25.7×

FCF Yield

1.77%

Div Yield (Net)

1.24%

Franking

100%

⚠️ Comparability Warning: Prior to 12 February 2025, Sigma Healthcare was a pharmaceutical wholesale distributor with ~A$4.8B revenue and paper-thin margins. On that date it acquired Chemist Warehouse via a reverse acquisition in which CW is deemed the acquirer for accounting purposes. All financials before FY2025 (ended 30 June 2025) reflect old Sigma or CW-standalone numbers and are not comparable to the merged group. This analysis is based on FY2025 (first full merged year) and H1 FY2026 (six months to 31 December 2025).

1. Business Overview

Sigma Healthcare is, in practical terms, the Australian pharmacy sector re-listed under a new guise. The legal entity is the old Sigma (a wholesaler); the economic engine is Chemist Warehouse — Australia's dominant pharmacy retail network with over 600 stores and a franchise model that generates high-margin fee income on top of product distribution. The February 2025 merger created a vertically integrated healthcare platform: CW franchisees buy product from Sigma's wholesale arm, pay franchise and marketing fees to the group, and operate under the CW brand. This vertical integration is the core of the investment thesis.

The group operates as a single Healthcare segment. Revenue comes from four streams: sale of goods to franchisees and third-party wholesaling (~93%), franchise and related fees (~2.5%), marketing and advertising fees (~2.9%), and international operations (primarily New Zealand, China, Ireland and UAE, ~4% of revenue). The capital-light franchise model means CW corporate does not own the pharmacies — it licences the brand and supplies product, keeping the balance sheet lean relative to the revenue base. This is structurally similar to McDonalds or 7-Eleven.

Revenue Stream	H1 FY2026 (A$M)	% of Total	Geography
Sale of goods (wholesale + direct)	5,135.7	93.2%	Primarily domestic
Fees and other revenue	75.2	1.4%	Domestic
Franchise and related fees	139.0	2.5%	Domestic
Marketing, advertising and other	158.6	2.9%	Domestic + intl
Total Revenue	5,508.5	100.0%

Geography	FY2025 Revenue (A$M)	% of Total	Non-current Assets (A$M)
Australia	5,654.2	94.2%	4,365.1
International	347.7	5.8%	54.5
Total	6,001.8	100.0%	4,419.6

2. Financial Performance

The financial profile of the merged group looks very different from either company in isolation. The wholesale distribution arm produces large revenue numbers at thin margins; the CW franchise operations layer in high-margin fee income. Understanding the blended result — and the structural margin compression visible in H1 FY2026 — is essential to any valuation work.

2.1 Income Statement

A$M	FY2025¹ (Jun 2025)	H1 FY2026 (Dec 2025)	H1 FY2025² (Dec 2024)	YoY Change
Revenue	6,001.8	5,508.5	1,963.7	+180.5%³
Cost of Sales	(4,561.5)	(4,500.7)	(1,286.4)	—
Gross Profit	1,440.3	1,007.8	677.3	+48.8%³
Gross Margin %	24.0%	18.3%	34.5%²	—
Warehousing & distribution	—	(175.4)	(82.3)	—
Marketing & sales	—	(65.5)	(44.5)	—
Admin & general	—	(229.2)	(135.0)	—
D&A	(56.0)	(42.4)	(19.6)	—
Normalised EBIT	806.4	582.9	446.1	+30.7%
Statutory EBIT	806.4	564.6	438.0	+28.9%
EBITDA	862.4	607.0	—	—
EBITDA Margin %	14.4%	11.0%	—	—
Net Finance Costs	(24.4)	(27.7)	(1.2)	—
Income Tax	(218.0)	(157.9)	(129.0)	—
Effective Tax Rate	29.3%	29.4%	29.5%	—
NPAT (attributable)	529.9	379.8	309.9	+22.6%
EPS (diluted, cents)	~5.0c	3.3c	3.1c	+5.4%

¹ FY2025 is the first full year of the merged entity (Sigma + Chemist Warehouse), year ended 30 June 2025. ² H1 FY2025 comparatives reflect Chemist Warehouse standalone operations only (pre-merger), making year-on-year revenue comparisons misleading. ³ Revenue and gross profit growth is primarily driven by consolidation of Sigma's wholesale operations, not organic growth.

Gross margin compression explained: The H1 FY2025 comparative (CW standalone) had a 34.5% gross margin reflecting CW's franchise fee–dominant revenue mix. H1 FY2026 shows 18.3% because Sigma's low-margin wholesale distribution (~$3.5B of product sales) is now consolidated. Going forward, 17–19% gross margin is a more representative steady-state expectation.

2.2 Balance Sheet Snapshot (31 December 2025)

Cash & Equivalents

A$160.5M

Comfortable liquidity

Bank Debt (excl. IFRS 16)

A$795.6M

Senior syndicated facility

Net Debt (excl. leases)

A$635.1M

Net Debt/EBITDA ~0.5×

IFRS 16 Lease Liabilities

A$1,206.9M

Store & DC leases (see note)

Total Assets

A$8,737.3M

Incl. A$3,857M goodwill/intangibles

Goodwill & Intangibles

A$3,857M

44.1% of total assets

Net Tangible Assets per share

A$0.09

Heavily intangible-heavy structure

Book Equity

A$4,890.7M

Price/Book = 6.3×

IFRS 16 lease liabilities are primarily store leases for CW's 600+ pharmacy network and Sigma distribution centres. These are genuine economic obligations — when assessing leverage, total obligations (net debt + leases) of ~$1,842M relative to annualised EBITDA of ~$1,214M gives a lease-inclusive net leverage of ~1.5×. The bank covenant uses an FCCR (Fixed Charge Coverage) test, not net debt/EBITDA; the group confirmed covenant compliance at December 2025.

2.3 Cash Flow Summary

A$M	FY2025 (Full Year)	H1 FY2026	H1 FY2025²
Operating Cash Flow (OCF)	598.8	317.4	428.7
Capital Expenditure	(57.6)	(23.5)	(29.1)
Free Cash Flow	541.3	293.9	399.6
Principal lease payments	—	(78.8)	(66.2)
Dividends paid	(1,186.0)¹	(149.5)	(148.9)
Net change in cash	(134.4)	21.7	232.5

¹ FY2025 dividends of A$1,186M includes a ~A$700M pre-merger Chemist Warehouse distribution to owners (classified as preferred dividends in LSEG data) and ongoing ordinary dividends. Ongoing dividend capacity should be assessed against the H1 FY2026 ordinary dividend of 2.0 cents per share × 11,501M shares = ~A$230M annualised. ² H1 FY2025 OCF reflects CW standalone (pre-merger), not comparable to merged group.

H1 FY2026 OCF commentary: The A$317.4M OCF is lower than the H1 FY2025 CW-standalone figure (A$428.7M) partly because: (i) the merged group now carries Sigma's larger working capital base; (ii) interest paid nearly doubled to A$55.9M reflecting the consolidated debt structure; and (iii) tax payments of A$51.5M in H1 reflect the larger combined tax base. H2 is typically stronger for CW given Christmas and summer health demand; I expect FY2026 full-year FCF of ~A$620–660M.

2.4 Dividend History

Period	DPS (cents)	Franking	Payment Date
H1 FY2026 Interim (Dec 2025)	2.0c	100%	20 March 2026
FY2025 Final	1.3c	100%	~Sep 2025
H1 FY2025 (CW pre-merger)	21.5c¹	100%	Pre-merger distribution

¹ The 21.5c H1 FY2025 dividend was paid by Chemist Warehouse to its private owners before the merger completed. Annualised post-merger DPS: ~3.3c (1.3c + 2.0c) = A$380M total payout (~50% of NPAT, consistent with policy).

3. Valuation — Enterprise DCF

3.1 WACC Build-up

Component	Input / Assumption	Value
Risk-free rate (10Y ACG yield)	10-year Australian Government Bond	4.40%
Equity Beta	Estimated 0.80 (stable pharmacy retail; newly listed merged entity)	0.80
Market Risk Premium (MRP)	Long-run ASX equity risk premium	6.0%
Cost of Equity	4.40% + 0.80 × 6.0%	9.20%
Pre-tax Cost of Debt	BBSW + ~1.5% credit spread (IG quality)	5.50%
After-tax Cost of Debt	5.50% × (1 − 29.4%)	3.88%
Target Equity Weight (E/V)	Post-integration capital structure target	75%
Target Debt Weight (D/V)		25%
WACC	0.75 × 9.20% + 0.25 × 3.88%	7.9%

Beta is estimated for the merged entity. The old Sigma had a low beta (~0.6) as a defensive pharmaceutical wholesaler; CW's franchise retail model has moderate cyclicality. I've used 0.80 as a pragmatic estimate for the new combined entity pending a longer listed-entity price history. WACC of 7.9% is used in the base case; I stress-test 7.0–9.0% in the sensitivity table.

3.2 DCF Assumptions — Three Scenarios

Given that FY2025 was the first full year of the merged group and H1 FY2026 annualises to approximately A$620–660M in FCF, I use FY2026E as the base year for the projection. The three scenarios capture (a) integration disappointment and margin compression; (b) steady execution in line with current run-rates; and (c) strong synergy realisation with international expansion.

Assumption	Bear	Base	Bull
Starting FCF (FY2026E, A$M)	580	680	850
FCF growth (Years 1–5)	5% p.a.	10% p.a.	18% p.a.
WACC	9.5%	7.9%	7.0%
Terminal growth rate	1.5%	3.0%	3.5%
Net Debt (incl. IFRS 16, A$M)	1,842	1,842	1,842
Shares on issue (M)	11,501	11,501	11,501
Implied Price per Share	A$0.55	A$1.37	A$2.84
Terminal Value as % of EV	~68%	~82%	~86%

3.3 Scenario Pricing

Bear Case

$0.55

Integration struggles; margin pressure; PBS reform headwinds

Base Case

$1.37

Steady execution, synergies moderate, 10% FCF CAGR

Bull Case

$2.84

Strong synergy capture, international growth, low WACC environment

Current Price

$2.66

Priced at near-bull-case execution level

Commentary: The current price of A$2.66 sits fractionally below my bull-case DCF estimate of A$2.84, implying the market is pricing in near-perfect execution. The base-case intrinsic value of A$1.37 represents approximately 48% downside if the integration underdelivers or if the capital markets re-rate the stock toward more conventional pharmacy/retail multiples. The wide scenario range (A$0.55–$2.84) reflects genuine uncertainty about what the normalised earnings power of this newly merged entity looks like at scale.

3.4 DCF Sensitivity — Implied Share Price (Base FCF Path)

All values in A$. Base case cell highlighted in blue. Base-case FCF path: A$680M in FY2026E growing at 10% per year for five years.

WACC \ TGR	1.5%	2.0%	2.5%	3.0%	3.5%
7.0%	$1.27	$1.39	$1.54	$1.72	$1.96
7.5%	$1.15	$1.25	$1.36	$1.51	$1.69
7.9%	$1.06	$1.15	$1.25	$1.37	$1.52
8.5%	$0.95	$1.02	$1.10	$1.20	$1.31
9.0%	$0.88	$0.94	$1.00	$1.08	$1.17

No cell in this base-case sensitivity table comes close to the current price of A$2.66. The sensitivity above uses a 10% FCF growth assumption. Justifying A$2.66 requires either: (i) substantially higher starting FCF (A$850M+ bull case), (ii) a much longer high-growth period (10–15 years at 18%+), or (iii) an ex-ante WACC well below 7.0%. The current market price appears to embed a "supercompounder" narrative that isn't yet supported by the first full year of reported numbers.

4. Valuation — Economic Profit Model

Metric	FY2025 (Merged)	FY2026E (Annualised H1)
NOPAT (A$M)	~569	~818
Average Invested Capital (A$M)	~6,602	~6,733
ROIC	8.6% (blended)¹	12.1%
ROIC (ex-goodwill)	~21%	~27%
WACC	7.9%	7.9%
ROIC − WACC Spread	+0.7%	+4.2%
Economic Profit (A$M)	~$46M	~$283M

¹ FY2025 ROIC uses average IC across the merger transition, which blends old Sigma's small IC base with the post-merger IC — this artificially inflates the LSEG-reported ROIC of 15.44%. My forward estimate of 12.1% (using Dec 2025 IC as denominator) is more representative. Return on tangible capital (excluding goodwill) of ~27% is exceptional and reflects the capital-light franchise model.

Commentary: The economics of Chemist Warehouse's underlying franchise operations are genuinely attractive — the model earns high returns on the tangible capital it deploys. However, the merged entity's total invested capital base of A$6.7B is dominated by the A$3.9B in goodwill and intangibles generated at the merger, which dilutes headline ROIC. The economic profit is positive and growing, which validates the franchise model. The problem is the valuation: at the current market price, the stock's Market Value Added (EV minus IC) is approximately A$24.5B — this is a claim on future economic profit that implies EP growing from ~A$283M today to roughly A$2B+ at steady state. That's a bold bet.

5. Valuation Summary — Football Field

The football field below plots the implied share-price range for each methodology against the current price of A$2.66. All three methods agree that at today's price, the stock is toward the upper end of fundamental value — supported only by the most optimistic scenario in each framework.

Enterprise DCF
(Bear $0.55 → Bull $2.84)

$0.55 – $2.84

EV/EBITDA Peer Comps
(12–25× fwd EV/EBITDA)

$1.11 – $2.48

Economic Profit Model
(Conservative range)

$0.85 – $1.95

$0 $1.00 $2.00 $2.66 $3.00

Valuation range

Current price (A$2.66)

Commentary: The current price of A$2.66 sits above the top end of the EV/EBITDA peer comps range and economic profit model range, and at the very top of the DCF bull-case. There is no methodology in this analysis that returns A$2.66 as a "fair value" under conservative or even moderate assumptions. This is not unusual for a newly-listed category dominant franchise business — the market frequently pays a premium for scarcity and network effects — but it does mean there is minimal margin of safety at the current price. The stock is priced for sustained execution.

6. Savings Account Test (FCF/EV)

Think of it this way: the enterprise value (A$31.2B) is the "deposit." The free cash flow (A$541.3M, FY2025) is the "interest payment." The FCF/EV ratio is the "interest rate" on your deposit.

1.73% FCF/EV

Enterprise Value: A$31.2B (ex-leases) | Annual FCF: A$541.3M (FY2025) | Data: 30 June 2025

Benchmark	Rate	SIG FCF/EV vs Benchmark	Result
RBA Cash Rate (risk-free)	4.35%	1.73% vs 4.35%	❌ Below
1-year term deposit	~4.80%	1.73% vs 4.80%	❌ Below
ASX 200 earnings yield (fwd)	~5.0%	1.73% vs 5.00%	❌ Below
Risk threshold (large-cap retail/healthcare)	~4.5–5.5%	1.73% vs 4.5–5.5%	❌ Below

Commentary: The savings account test delivers a clear verdict: at A$2.66, Sigma Healthcare's current FCF yield offers 1.73% on enterprise value — less than half the risk-free rate. An investor buying today is effectively paying a large premium for future growth rather than current cash generation. This is only rational if you believe FCF will grow strongly enough to justify the premium over time. Using H1 FY2026 annualised FCF (~A$590M) at the current EV lifts the FCF/EV to roughly 1.89% — still firmly in "growth story" territory. To get to a 4.5% FCF/EV yield at the current price, FCF would need to grow to approximately A$1.4B — more than 2.5× current levels. That's achievable but requires a long runway and strong execution.

7. Allen/Plato Red Flag Assessment

Flags

Watches

Clears

#	Category	Status	Detail
1	Negative Operating Cash Flow	CLEAR	OCF of A$598.8M (FY2025) and A$317.4M (H1 FY2026). Strongly positive. No concern.
2	Earnings–Cash Flow Divergence	WATCH	H1 FY2026: NPAT A$379.8M vs OCF A$317.4M. Earnings exceed OCF partly due to large working capital build (receivables up A$270M vs Jun 2025). Monitor for sustained divergence in H2 FY2026.
3	Excessive Debt	WATCH	Bank debt/EBITDA ~0.5× (manageable). But total obligations including IFRS 16 leases = A$1,842M net against annualised EBITDA ~A$1,214M → net leverage ~1.5×. Refinanced facility in H1 FY2026 at longer tenors. Covenant (FCCR ≥ 2.0×) comfortably met.
4	Insider Selling	CLEAR	No evidence of significant insider share sales in the disclosed period. The Gance and Verrocchi families remain major stakeholders and are aligned with the long-term success of the business.
5	Executive Remuneration	CLEAR	Share-based payments expense of A$5.35M in H1 FY2026 is modest relative to the A$5.5B revenue base (~0.1% of revenue). Remuneration structure appears reasonable.
6	Corporate Governance	FLAG	The Gance and Verrocchi families retain significant influence as founders and board representatives (Mr J Gance, Mr M Verrocchi, Ms D Di Pilla listed as directors). The merger was structured to benefit these private CW owners. Board independence and protection of minority shareholders warrants ongoing scrutiny given concentrated founder control.
7	Related Party Transactions	FLAG	Note 9 of the H1 FY2026 accounts discloses substantial RPTs: A$951.5M in goods sold to KMP-controlled franchised stores; A$312.5M trade receivables from KMP entities; A$248.2M in lease liabilities to properties owned by KMP. While these reflect the normal franchise model, the scale and the fact that KMP controls both sides of these transactions is a governance concern that needs disclosure monitoring.
8	Auditor Quality	CLEAR	PricewaterhouseCoopers (PwC) — Big 4 firm. Clean review opinion issued 26 February 2026. No modified opinion, emphasis of matter or other matter paragraph.
9	Aggressive Growth Expectations	FLAG	Stock trades at 25.7× fwd EV/EBITDA and 40.3× fwd P/E. The DCF only reaches the current price under bull-case assumptions (18% FCF CAGR, WACC 7.0%, TGR 3.5%). All base-case scenarios produce intrinsic values well below market. The growth priced-in is extraordinary for a large-cap; execution risk is high.
10	High Beta / Volatility	WATCH	As a newly-listed merged entity (listed in its current form only since Feb 2025), SIG lacks a meaningful price history. Beta estimate of 0.80 is based on peer analysis. The stock has re-rated from ~A$1.03 (Jan 2024 pre-merger announcement) to A$2.99 (Jun 2025) and is now at A$2.66 — notable volatility at a large market cap. Higher beta risk than the estimate implies.
11	Non-Standard Performance Metrics	WATCH	The company reports "Normalised EBIT" that excludes integration costs (A$16.0M), merger-related costs, and PPA (purchase price allocation) charges. While these adjustments are disclosed, the normalisation gap of A$18.3M in H1 FY2026 will persist for 2–3 years of integration. Investors should track whether one-off costs become recurring.
12	Overstated Receivables / Inventory	WATCH	Trade receivables grew from A$921.9M (Jan 2025) to A$1,527.8M (Jun 2025) to A$1,845.6M (Dec 2025) — a 100% increase in 11 months partly reflecting the larger merged business. Receivables-to-revenue DSO appears stretched. Inventory grew modestly (+A$94.5M to A$1,114.3M). The receivables growth is partly structural (Sigma distributes on credit to pharmacies) but the rate of growth warrants attention.

⚠️ CAUTION — 3 FLAGS, 5 WATCHES

3 FLAGS + 5 WATCHES = 8 combined items, placing SIG.AX at the top of the CAUTION range / bottom of DANGER. The governance and related-party concerns are structural to the business model and unlikely to improve; the aggressive-growth flag and receivables watch items are valuation-driven and would diminish if the stock re-rated lower. Investors should monitor H2 FY2026 results closely for: (i) working capital normalisation, (ii) integration cost run-off, and (iii) any changes to founder control.

8. Risks & Considerations

PBS Reform and regulatory pricing pressure. Pharmaceutical Benefits Scheme pricing reforms remain an ongoing threat to pharmacy economics. The Australian Government continues to review dispensing fees, pharmacist remuneration, and medicine co-payments. Any step-down in PBS dispensing margins hits both Sigma's wholesale volumes and the franchisee economics that support CW's network. A 5% reduction in PBS dispensing revenue would meaningfully dent group profitability.

Integration execution risk. The merger of two businesses with different cultures, IT systems, supply chains, and financial year-ends is inherently risky. Sigma is absorbing A$16M in integration costs in H1 FY2026 alone, and management acknowledges this will continue. The risk is that promised synergies (combined purchasing scale, shared distribution infrastructure, data analytics) take longer to materialise than the market has priced in. The "easy wins" — brand synergies, marketing coordination — are already delivered; the harder operational integration is ongoing.

Concentration of related-party economic activity. The Gance and Verrocchi families own and operate a significant portion of the CW franchised store network — the same network that Sigma supplies product to and receives franchise fees from. This creates a structure where a small number of individuals benefit from both the franchisor side (dividends/distributions from Sigma shareholdings) and the franchisee side (store-level profitability). Minority shareholders have limited visibility into the arm's-length quality of these arrangements. Any deterioration in franchisee profitability could prompt franchise renegotiations that favour the operator families.

Working capital and cash conversion cycle. Sigma's wholesale distribution model extends credit to pharmacy customers, generating large trade receivables. With A$1.8B in receivables at December 2025 on a 12-month revenue run-rate of ~A$11B, any deterioration in customer collections (e.g., a pharmacy chain insolvency or PBS payment delays) could create significant cash flow volatility. Management needs to demonstrate H2 FY2026 working capital normalisation to maintain market confidence.

Valuation re-rating risk. The stock's current 40× forward P/E and 26× forward EV/EBITDA leave virtually no room for earnings misses. Global capital market conditions have become increasingly sensitive to duration risk in long-dated growth equities. Should Australian long-term interest rates rise materially from current levels — compressing the equity risk premium — or should the integration timeline slip, the stock could de-rate sharply toward more conventional pharmacy-retail multiples (12–18× EV/EBITDA), implying 30–50% downside.

Pharmacy Guild and labour market dynamics. A structural feature of the CW model is its deep-discount pharmacy positioning, which has historically put it in tension with the Pharmacy Guild of Australia (which represents independent pharmacies). CW's growth has benefited from regulatory changes; any reversal — such as restrictions on pharmacy ownership, location proximity rules, or changes to the 1-per-location pharmacy ownership model — could constrain the store expansion that underpins the growth story.

9. Analyst Consensus

Analyst consensus data was not available in the data provided for this report. SIG.AX, having only completed its transformation via the CW merger in February 2025, is still building its analyst coverage universe. Major brokers who have initiated or maintained coverage as of early 2026 generally hold a positive outlook on the franchise model but note premium valuation as a risk. Refer to your broker platform for up-to-date target prices and recommendations.

This section will be updated when broker consensus data is available. As an indication of market sentiment: the stock has declined from A$2.99 (Jun 2025) to A$2.66 (Mar 2026), suggesting some de-rating of initial post-merger enthusiasm.

Sigma Healthcare (SIG.AX) — Plain English Summary

Current Price: A$2.66 | Market Cap: A$30.6B | 30 March 2026

1. What Does Sigma Healthcare Do?

Sigma Healthcare is, in practical terms, the company that owns and operates the Chemist Warehouse franchise network — those bright yellow discount pharmacies you see everywhere in Australia. The group runs the brand, supplies the medicine and products, and collects fees from the 600+ individually owned pharmacy stores that operate under the Chemist Warehouse flag.

It merged with the old "Sigma" pharmaceutical delivery company in early 2025, giving it a combined business that earns money three ways: (1) selling medicine and health products wholesale to pharmacies, (2) collecting franchise fees from CW store owners, and (3) running an international operation in New Zealand, China, Ireland, and the UAE.

2. How Has the Business Been Performing?

The numbers look impressive on the surface. For the six months to December 2025, the combined business took in A$5.5 billion in revenue and earned A$380 million in profit — a respectable result. Year-on-year comparisons show explosive "growth," but this is misleading: the jump in revenue is almost entirely because 2025 was the first period where both Sigma and Chemist Warehouse were counted together.

Looking at the underlying business, the picture is solid but not spectacular. Profit margins have actually fallen (from 34% to 18% on gross profit) because the big Sigma wholesale arm earns thinner margins than the CW franchise operations did on their own. The business generates real cash — about A$540 million per year — which is healthy. The company pays a fully-franked dividend (2.0 cents for the recent half-year period), and its debt level is manageable.

The most important ongoing story is whether the merger is creating value. Early signs are encouraging: integration work is progressing, the combined purchasing power should reduce product costs over time, and the CW brand continues to attract customers.

3. What Is It Actually Worth?

This is where the story gets challenging. My three valuation scenarios produce a wide range of estimated "fair values":

Cautious view: A$0.55 per share — if the merger integration stumbles or pharmacy sector conditions deteriorate
Central view: A$1.37 per share — based on reasonable growth expectations and a normal discount rate
Optimistic view: A$2.84 per share — if CW delivers strong growth for many years and the discount rate stays low

The current share price is A$2.66, which sits almost exactly at my most optimistic estimate. That's not the same as saying the stock is overvalued — it means the market is betting on Chemist Warehouse delivering excellent performance for a very long time. If that happens, A$2.66 is fair. If it doesn't, there's meaningful downside.

Using peer company comparisons (how similar businesses trade), the stock looks expensive at 26× next year's operating profit (EBITDA), compared to large Australian retailers which typically trade at 12–18×. The premium reflects the CW network's dominant market position and the scarcity of owning a business like this.

4. The Savings Account Test

Imagine you're depositing A$31.2 billion (the total enterprise value) into a special "business savings account." In return, you'd receive the A$541 million per year in free cash flow the business generates. That's an "interest rate" of just 1.73% per year.

Compare that to:

RBA cash rate: 4.35% — the risk-free government rate ❌
Bank term deposit: ~4.80% ❌
Average ASX 200 company: ~5.0% ❌

You're earning less than half the risk-free rate on the current investment. This doesn't mean the stock is a bad investment — it means you're paying for future growth, not current income. For the economics to work out, the cash the business generates needs to roughly triple over the next 8–10 years. That's possible given CW's store rollout plans, but it's not guaranteed.

5. Are There Any Red Flags?

My analysis found 3 red flags and 5 amber warnings — placing the stock in the Caution category.

The main concerns are:

Founder control and related-party dealings: The Gance and Verrocchi families — who founded Chemist Warehouse — still own and operate a large chunk of the franchised stores, while also sitting on the board of the listed company. This means the same families earn money on both sides of the franchise relationship. It's legal and disclosed, but it's a concentration of power that minority shareholders should monitor.
The price is priced for perfection: At 40× next year's earnings, the stock can't afford a bad result. Any slip in growth or margin will likely cause a sharp price fall.
Growing receivables: The amount of money owed to Sigma by pharmacies has grown quickly — worth watching to ensure customers are paying on time.

On the positive side: the auditor is PwC (a Big 4 firm), debt levels are manageable, cash flow is real and growing, and the founding families haven't been selling shares.

6. Bottom Line

Sigma Healthcare (Chemist Warehouse) is a genuinely great business — dominant brand, capital-light franchise model, real cash generation, and a clear growth runway. The question is whether you're paying a fair price for it.

At A$2.66, you're paying for a lot of future growth that hasn't happened yet. My central valuation estimate is around A$1.37 — about half the current price. The only way to get to A$2.66 in a model is to assume everything goes right for a very long time. That's possible. CW is the kind of business that could justify a premium. But there's minimal margin for error.

In one sentence: Excellent business, demanding price — suitable for investors who believe in the CW franchise compounding story and can tolerate premium valuation risk.